摘要
来那度胺是一种新型免疫调节剂,是沙利度胺的衍生物,对于血液系统疾病具有较高的治疗反应率和安全性。本文的目的在于评估来那度胺在复发难治性多发性骨髓瘤、复发难治性慢性淋巴细胞性白血病、复发难治性急性髓系白血病、复发难治性非霍奇金淋巴瘤、复发难治性经典型霍奇金淋巴瘤、复发难治性POEMS综合征疾病的治疗中的疗效及安全性,就来那度胺在复发难治性血液系统疾病中的最新临床研究及其应用进展作一综述。
Lenalidomide, a novel immunomodulatory agent, is a kind of thalidomide derivatives, which shows a good efficacy and safety for hematological system diseases. This review is aimed to evaluate the efficacy and safety of lenalidomide in treatment of patients with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin＇s lymphoma, classical Hodgkin＇s lymphoma and POEMS syndrome at their replased or refractory state. At the same time, this review focuses on the newest clinical research and the latest application progress of lenalidomide for relapsed or refractory hematological system diseases,
作者
樊文静
范枝俏
吴涛
白海
FAN Wen-Jing1,2, FAN Zhi-Qiao1 reviewer, WU Tao1 , BAI Hai1 revisors(1 Center of Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Province, China; 2 The Second Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, Chin)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2018年第2期595-599,共5页
Journal of Experimental Hematology
基金
甘肃省自然科学基金(145RJZA151)
